0
Your cart

Your cart is empty

Books > Medicine > Other branches of medicine > Pharmacology

Buy Now

Polymyxin Antibiotics: From Laboratory Bench to Bedside (Hardcover, 1st ed. 2019) Loot Price: R5,349
Discovery Miles 53 490
Polymyxin Antibiotics: From Laboratory Bench to Bedside (Hardcover, 1st ed. 2019): Jian Li, Roger L. Nation, Keith S. Kaye

Polymyxin Antibiotics: From Laboratory Bench to Bedside (Hardcover, 1st ed. 2019)

Jian Li, Roger L. Nation, Keith S. Kaye

Series: Advances in Experimental Medicine and Biology, 1145

 (sign in to rate)
Loot Price R5,349 Discovery Miles 53 490 | Repayment Terms: R501 pm x 12*

Bookmark and Share

Expected to ship within 10 - 15 working days

This volume is the first-ever complete treatise on polymyxins and presents the most comprehensive and up-to-date reviews of all major research and clinical topics from chemistry, microbiology, pharmacology, clinical use, to drug discovery. All chapters were written by internationally leading researchers and clinicians in the field. It is our wish that readers discover the importance of polymyxin structure in relation to the mechanisms of activity, resistance and toxicity. We emphasized that reliable analytic methods for polymyxins are critical when investigating their pharmacokinetics (PK) and pharmacodynamics (PD). The complicated dose definitions and different pharmacopoeial standards have already compromised the safe use of polymyxins in patients. Therefore, informed by the latest pharmacological information, scientifically-based dosing recommendations have been proposed for intravenous polymyxins. Considering the PK/PD limitations and potential development of resistance, polymyxin combinations are encouraged; however, the current literature has not shown definite microbiological benefits, possibly because most clinical studies to date overlooked key PK/PD principles. Nephrotoxicity is the major dose-limiting factor and it is imperative to elucidate the mechanisms and develop novel approaches to minimize polymyxin-associated toxicities. In addition, the anti-endotoxin effect of polymyxins supports their clinical use to treat Gram-negative sepsis. Fortunately, the discovery of new-generation polymyxins with wider therapeutic windows has benefited from the latest achievements in polymyxin research. This book provides extensive pharmacological information on polymyxins to infectious diseases clinicians, pharmacists, clinical microbiologists, antimicrobial pharmacologists, and pharmaceutical scientists, and is an essential read for those who aim to develop novel polymyxins and improve their clinical use as a last-line defense against Gram-negative 'superbugs'.

General

Imprint: Springer Nature Switzerland AG
Country of origin: Switzerland
Series: Advances in Experimental Medicine and Biology, 1145
Release date: August 2019
First published: 2019
Editors: Jian Li • Roger L. Nation • Keith S. Kaye
Dimensions: 254 x 178mm (L x W)
Format: Hardcover
Pages: 366
Edition: 1st ed. 2019
ISBN-13: 978-3-03-016371-6
Categories: Books > Medicine > Other branches of medicine > Pharmacology > General
Books > Science & Mathematics > Biology, life sciences > Microbiology (non-medical) > Bacteriology
LSN: 3-03-016371-7
Barcode: 9783030163716

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Partners